The 96-week study compared 86 men previously taking elvitegravir-cobicistat-FTC-TAF (Stribild, Gilead) or a tenofovir disoproxil fumarate–based regimen with BIC/FTC/TAF. Ultimately, 77 men completed the study. Patients who switched to BIC/FTC/TAF achieved virologic suppression rates of 94.2% and 74.4% at weeks 72 and 96, respectively.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045